Tirzepatide
Also known as: Tirzepatide (GIP/GLP-1 dual receptor agonist — Mounjaro, Zepbound)
Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It is FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It carries a BOXED WARNING for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Who's worth your money for Tirzepatide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 22 scored sellers
$1800 · 1200mg · 99.1% purity
Best value
Lowest $/mg among scored sellers
$10.00 · 20mg · 99.8% purity
Most tested
57 independent COAs on file
$158 · 40mg · 99.9% purity
Average price
$3.95/mg
Sellers
44
45-day trend
-20.1%
37 of 44 sellers have a current price· 9 stale hidden· 6 unverified hidden
Top Merit pick
🇺🇸 Peptide Partners99via Disclosed Labs · 10h ago
$1.50/mg -62.1% vs avg$1800
1200mg
- 🇺🇸 Licensed Peptides95
✓ verified at source · 3d ago · stale
$1.80/mg -54.5% vs avg$53.99
30mg
no purityBuy Code MERIT · 5% off - 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · 10h ago
$3.33/mg -15.7% vs avg$200
60mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 10h ago
$3.95/mg -0.1% vs avg$158
40mg
- 🇺🇸 Prime Peptides95
via Disclosed Labs · 10h ago
$4.33/mg +9.6% vs avg$260
60mg
- 🇺🇸 Sunrise Bioresearch94
via Disclosed Labs · 10h ago
$1.20/mg -69.5% vs avg$361
300mg
- 🇺🇸 Forge Performance Co.94
via Disclosed Labs · 10h ago
$3.33/mg -15.7% vs avg$100
30mg
- Nova Peptides94
via Disclosed Labs · 10h ago
$3.50/mg -11.5% vs avg$350
100mg
no purity - 🇺🇸 Ignite Peptides93
via Disclosed Labs · 10h ago
$5.00/mg +26.4% vs avg$150
30mg
- 🇺🇸 Riptide Wellness92
via Disclosed Labs · 10h ago
$3.00/mg -24.1% vs avg$180
60mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Tirzepatide
Get one email when the market actually moves — no newsletter, no noise.
About Tirzepatide
CAS
2023788-19-2
Molecular formula
C225H348N48O68
Sequence
YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPSamide
Typical dose range
2.5–15 mg once weekly subcutaneous injection (research studies mirror clinical titration: start 2.5 mg/week, escalate by 2.5 mg every 4 weeks to max 15 mg/week)
Half-life
~5 days (~120 hours)
COAs for Tirzepatide
452 third-party tests across 55 vendors. Each card links to the full report.
For
Tirzepatide
by Sunrise Bioresearch· batch GLP230JUL26-01
For
Tirzepatide
by Crush Research· batch CR-2XAG-60-2607-Purple
For
Tirzepatide
by jdbioworks· batch 2026-002
For
Tirzeptide
by Ignite Peptides· batch IP-2607-127
For
Tirzepatide
by Ignite Peptides· batch IP-2607-797
For
Tirzepatide
by NG Peptide· batch TRZ40-15
For
Tirzepatide
by Hydro Research Peptides· batch HR-2026-3814
For
Tirzepatide
by NG Peptide· batch TRZ20-14
For
Tirzepatide
by NG Peptide· batch TRZ20-14
For
Tirzepatide
by Aspire Peptides· batch TR10-032026-1
For
Tirzepatide
by Aspire Peptides· batch TR15-032026-1
For
Tirzepatide
by Polaris Peptides· batch POL-T10-19
For
Tirzepatide
by Orbitrex Peptides· batch 2G30726
For
Tirzepatide
by Ion Peptide· batch ION2T20-06242026
For
Tirzepatide
by Profound Aminos· batch Clear Cap/Bronze Crimp
For
Tirzepatide
by Blank Peptides· batch GT10-062026-6
For
Tirzepatide
by Soma Peptides· batch TIXH0062661
For
Tirzepatide
by Peptide Partners· batch SPL-4130
For
Tirzepatide
by NG Peptide· batch TRZ30-13
For
Tirzepatide
by NG Peptide· batch TRZ30-13
For
Tirzepatide
by Peptide Plugs· batch 005-B-SM
For
Tirzepatide
by NG Peptide· batch TRZ60-04
For
Tirzepatide
by Voltera Sciences· batch TR60.05.28.26
For
Tirzepatide
by Soma Peptides· batch TILX052678
23 citations indexed for Tirzepatide
meta-analysis · 2026
Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies
This systematic review and meta-analysis aimed to compare the efficacy and safety of tirzepatide versus semaglutide for weight reduction in adults with overweight or obesity. We included randomised controlled trials and observational studies comparing tirzepatide and semaglutide with ≥ 24 weeks of follow-up.
Study · 2026
Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort Study
Background While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promise in improving respiratory outcomes, the comparative effectiveness of dual glucose-dependent insulinotropic polypeptide/GLP-1 RA versus GLP-1 RA alone remains unclear.
animal · 2026
Increased Energy Expenditure through Intermittent Cold Exposure Does Not Enhance Tirzepatide Induced Weight-loss in Obese Mice
Obesity results from an imbalance between energy intake and energy expenditure.
rct · 2026
Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA
Purpose Obstructive sleep apnea (OSA) is a common disorder characterized by repetitive collapse of the upper airway during sleep.
review · 2026
Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era
Background Heart failure with preserved ejection fraction (HFpEF) accounts for over half of all heart failure hospitalizations, with obesity increasingly recognized as a central driver through expansion of epicardial adipose tissue, chronic low-grade inflammation and obesity-related haemodynamic overload culminating in…
Study · 2026
Unilateral Graves' Disease Developing During Treatment With Tirzepatide in a Patient With Diabetes: A Case Report
Background Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor, demonstrates significant efficacy in lowering blood glucose levels and reducing body weight.